In vitro effects of β3‐adrenoceptor agonist mirabegron on the human ureter
- 25 April 2024
- journal article
- research article
- Published by Wiley in Neurourology and Urodynamics
- Vol. 43 (7) , 1709-1717
Abstract
Introduction: This study aimed to investigate the effect of mirabegron, a β3‐adrenoceptor agonist with widespread clinical use for treating overactive bladder disease, on isolated healthy human ureter strips.Materials and Methods: This was a prospective study employing a series of in vitro organ bath experiments using ureteral tissues of kidney grafts from 10 healthy donors. The ureteral strips were subjected to cumulative mirabegron concentrations (10−9–10−4.5 M). Effects on frequency or amplitude of spontaneous, 10 mM KCl‐ or EFS‐induced contractions were evaluated.Results: Mirabegron decreased the frequency of spontaneous ureteric contraction in a concentration‐dependent manner. Statistically significant decrease in the frequency of spontaneous contraction was observed at 10−8–10−4.5 M. In 10 mM KCl medium, statistically significant change in frequency was observed at 10−9–10−4.5 M. Statistically significant decrease in the amplitudes of spontaneous contraction was observed at 10−7–10−4.5 M. In a 10 mM KCl medium, statistically significant change in amplitudes was observed at 10−8–10−4.5 M.Conclusions: Mirabegron reduced the amplitude and frequency of human ureter activity in in vitro organ bath studies. This effect was achieved in a dose‐dependent manner on isolated tissue strips. Although monotherapy with mirabegron remains uncertain, this study has the potential to elucidate the mechanism underlying the effectiveness of mirabegron, particularly in combination therapy for ureteral stones.Keywords
This publication has 45 references indexed in Scilit:
- Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stonesInternational Urology and Nephrology, 2023
- Efficacy of silodosin or mirabegron in medical expulsive therapy for ureteral stones: a prospective, randomized-controlled studyInternational Urology and Nephrology, 2019
- Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug‐Drug Interaction for Fesoterodine When Coadministered With MirabegronThe Journal of Clinical Pharmacology, 2019
- Adjunction of tamsulosin or mirabegron before semi-rigid ureterolithotripsy improves outcomes: prospective, randomized single-blind studyInternational Urology and Nephrology, 2019
- Combination of solifenacin and tamsulosin may provide additional beneficial effects for ureteral stent-related symptoms—outcomes from a network meta-analysisWorld Journal of Urology, 2018
- Contractile responses in intact and mucosa-denuded human ureter—a comparison with urinary bladder detrusor preparationsNaunyn-Schmiedeberg's Archives of Pharmacology, 2018
- Expression of β-adrenergic receptor subtypes in human normal and dilated ureterInternational Urology and Nephrology, 2017
- Beta‐3 adrenergic receptor is expressed in acetylcholine‐containing nerve fibers of the human urinary bladder: An immunohistochemical studyNeurourology and Urodynamics, 2017
- Modification of ureteral motility and promotion of urine flow around an intraureteral obstruction by CL‐316243, phenylephrine, and furosemide in dogsNeurourology and Urodynamics, 2002
- Effects of prostaglandin synthetase inhibitors on the upper urinary tractUrological Research, 1990